Company Filing History:
Years Active: 2025
Title: The Innovations of Davis Goodnight
Introduction
Davis Goodnight is a notable inventor based in Seattle, WA (US). He has made significant contributions to the field of biotechnology, particularly in the development of novel protein variants. With a total of 2 patents to his name, Goodnight's work focuses on enhancing the functionality and stability of important biological molecules.
Latest Patents
Goodnight's latest patents include innovations in interferon alpha-2 variants and interleukin 21 variants. The interferon alpha-2 variants are designed to have decreased or no detectable binding to the human interferon-alpha/beta receptor beta 2 (IFNAR2) compared to the wild-type human IFNA2 polypeptide. Additionally, these patents describe fusion proteins that covalently link an antibody or its fragment to the human IFNA2 variant. The interleukin 21 variants, on the other hand, exhibit decreased or no binding to the human interleukin 21 receptor (IL-21R) and increased stability compared to the wild-type human IL-21 polypeptide. These advancements have the potential to improve therapeutic applications in immunology.
Career Highlights
Davis Goodnight is currently associated with A-alpha Bio, Inc., where he continues to push the boundaries of biotechnological research. His work has garnered attention for its innovative approach to protein engineering and its implications for medical treatments.
Collaborations
Goodnight collaborates with talented individuals such as Emily Engelhart and Ryan Swanson, contributing to a dynamic research environment that fosters innovation and creativity.
Conclusion
Davis Goodnight's contributions to biotechnology through his patents and collaborations highlight his role as a leading inventor in the field. His work not only advances scientific knowledge but also holds promise for future medical breakthroughs.